23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material

G. Vladimer; I. Alt; R. Sehlke; A. Lobley; C. Baumgärtler; M. Stulic; K. Hackner; L. Dzurillova; E. Petru; L. Hadjari; J. Lafleur; J. Singer; N. Krall; J. Šufliarsky; L. Hefler; T. Fuereder; C. Taubert; C. Boudesco; A. Payne

doi:10.1016/j.iotech.2022.100128

23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material

G. Vladimer, I. Alt, R. Sehlke, A. Lobley, C. Baumgärtler, M. Stulic, K. Hackner, L. Dzurillova, E. Petru, L. Hadjari, J. Lafleur, J. Singer, N. Krall, J. Šufliarsky, L. Hefler, T. Fuereder, C. Taubert, C. Boudesco, A. Payne

Research output: Journal article (peer-reviewed) › Conference contribution to journal

Original language	English
Pages (from-to)	100128
Journal	Immuno-Oncology and Technology
Volume	16
DOIs	https://doi.org/10.1016/j.iotech.2022.100128
Publication status	Published - 01 Dec 2022

Access to Document

10.1016/j.iotech.2022.100128Licence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S2590018822000594

Cite this

Vladimer, G., Alt, I., Sehlke, R., Lobley, A., Baumgärtler, C., Stulic, M., Hackner, K., Dzurillova, L., Petru, E., Hadjari, L., Lafleur, J., Singer, J., Krall, N., Šufliarsky, J., Hefler, L., Fuereder, T., Taubert, C., Boudesco, C., & Payne, A. (2022). 23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material. Immuno-Oncology and Technology, 16, 100128. https://doi.org/10.1016/j.iotech.2022.100128

@article{2540efefc3bb4aa5ae14461ad6bb4b54,

title = "23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material",

author = "G. Vladimer and I. Alt and R. Sehlke and A. Lobley and C. Baumg{\"a}rtler and M. Stulic and K. Hackner and L. Dzurillova and E. Petru and L. Hadjari and J. Lafleur and J. Singer and N. Krall and J. {\v S}ufliarsky and L. Hefler and T. Fuereder and C. Taubert and C. Boudesco and A. Payne",

year = "2022",

month = dec,

day = "1",

doi = "10.1016/j.iotech.2022.100128",

language = "English",

volume = "16",

pages = "100128",

journal = "Immuno-Oncology and Technology",

issn = "2590-0188",

publisher = "Elsevier Inc.",

}

Vladimer, G, Alt, I, Sehlke, R, Lobley, A, Baumgärtler, C, Stulic, M, Hackner, K, Dzurillova, L, Petru, E, Hadjari, L, Lafleur, J, Singer, J, Krall, N, Šufliarsky, J, Hefler, L, Fuereder, T, Taubert, C, Boudesco, C & Payne, A 2022, '23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material', Immuno-Oncology and Technology, vol. 16, pp. 100128. https://doi.org/10.1016/j.iotech.2022.100128

TY - JOUR

T1 - 23P Enriching for response: Patient selection criteria for A2AR inhibition by EXS-21546 through ex vivo modelling in primary patient material

AU - Vladimer, G.

AU - Alt, I.

AU - Sehlke, R.

AU - Lobley, A.

AU - Baumgärtler, C.

AU - Stulic, M.

AU - Hackner, K.

AU - Dzurillova, L.

AU - Petru, E.

AU - Hadjari, L.

AU - Lafleur, J.

AU - Singer, J.

AU - Krall, N.

AU - Šufliarsky, J.

AU - Hefler, L.

AU - Fuereder, T.

AU - Taubert, C.

AU - Boudesco, C.

AU - Payne, A.

PY - 2022/12/1

Y1 - 2022/12/1

U2 - 10.1016/j.iotech.2022.100128

DO - 10.1016/j.iotech.2022.100128

M3 - Conference contribution to journal

SN - 2590-0188

VL - 16

SP - 100128

JO - Immuno-Oncology and Technology

JF - Immuno-Oncology and Technology

ER -